blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3788035

EP3788035 - SOLID FORMS OF CERDULATINIB [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  05.07.2024
Database last updated on 02.11.2024
FormerGrant of patent is intended
Status updated on  12.03.2024
FormerExamination is in progress
Status updated on  23.02.2023
FormerRequest for examination was made
Status updated on  05.02.2021
FormerThe international publication has been made
Status updated on  08.11.2019
Formerunknown
Status updated on  03.06.2019
Most recent event   Tooltip12.07.2024New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
Alexion Pharmaceuticals, Inc.
121 Seaport Boulevard
Boston, MA 02210 / US
[2024/28]
Former [2021/10]For all designated states
Portola Pharmaceuticals, Inc.
270 East Grand Avenue Suite 22 South San Francisco
California 94080 / US
Inventor(s)01 / PANDEY, Anjali
c/o Portola Pharmaceuticals, Inc.
270 E. Grand Ave., Suite 22
South San Francisco, California 94080 / US
02 / NORTHEN, Julian Scott
c/o Onyx Scientific Limited, Silverbriar
Enterprise Park East
Sunderland, Tyne and Wear SR5 2TQ / GB
03 / FERNANDES, Philippe
c/o Onyx Scientific Limited, Silverbriar
Enterprise Park East
Sunderland, Tyne and Wear SR5 2TQ / GB
04 / CHEN, Ying
c/o Portola Pharmaceuticals, Inc.
270 E. Grand Ave., Suite 22
South San Francisco, California 94080 / US
05 / LU, Yuelie
5115 Ruette De Mer
San Diego, California 92130 / US
06 / KARABORNI, Sami
c/o Portola Pharmaceuticals, Inc.
270 E. Grand Ave., Suite 22
South San Francisco, California 94080 / US
07 / KODERSHA, Gus
c/o Portola Pharmaceuticals, Inc.
270 E. Grand Ave., Suite 22
South San Francisco, California 94080 / US
 [2024/15]
Former [2024/07]01 / PANDEY, Anjali
c/o Portola Pharmaceuticals, Inc.
270 E. Grand Ave., Suite 22
South San Francisco, California 94080 / US
02 / NORTHEN, Julian Scott
c/o Onyx Scientific Limited, Silverbriar
Enterprise Park East
Sunderland, Tyne and Wear SR5 2TQ / GB
03 / FERNANDES, Philippe
c/o Onyx Scientific Limited, Silverbriar
Enterprise Park East
Sunderland Tyne and Wear SR5 2TQ / GB
04 / CHEN, Ying
c/o Portola Pharmaceuticals, Inc.
270 E. Grand Ave., Suite 22
South San Francisco, California 94080 / US
05 / LU, Yuelie
5115 Ruette De Mer
San Diego, California 92130 / US
06 / KARABORNI, Sami
c/o Portola Pharmaceuticals, Inc.
270 E. Grand Ave., Suite 22
South San Francisco, California 94080 / US
07 / KODERSHA, Gus
c/o Portola Pharmaceuticals, Inc.
270 E. Grand Ave., Suite 22
South San Francisco, California 94080 / US
Former [2021/10]01 / PANDEY, Anjali
c/o Portola Pharmaceuticals, Inc. 270 E. Grand
Ave., Suite 22 South
San Francisco, California 94080 / US
02 / NORTHEN, Julian Scott
c/o Onyx Scientific Limited Silverbriar
Enterprise Park East
Sunderland, Tyne and Wear SR5 2TQ / GB
03 / FERNANDES, Philippe
c/o Onyx Scientific Limited Silverbriar
Enterprise Park East
Sunderland Tyne and Wear SR5 2TQ / GB
04 / CHEN, Ying
c/o Portola Pharmaceuticals, Inc. 270 E. Grand
Ave., Suite 22 South
San Francisco, California 94080 / US
05 / LU, Yuelie
5115 Ruette De Mer
San Diego, California 92130 / US
06 / KARABORNI, Sami
c/o Portola Pharmaceuticals, Inc. 270 E. Grand
Ave., Suite 22 South
San Francisco, California 94080 / US
07 / KODERSHA, Gus
c/o Portola Pharmaceuticals, Inc. 270 E. Grand
Ave., Suite 22 South
San Francisco, California 94080 / US
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2024/32]
Former [2021/10]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date19726240.503.05.2019
[2021/10]
WO2019US30717
Priority number, dateUS201862667226P04.05.2018         Original published format: US 201862667226 P
[2021/10]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2019213606
Date:07.11.2019
Language:EN
[2019/45]
Type: A2 Application without search report 
No.:EP3788035
Date:10.03.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 07.11.2019 takes the place of the publication of the European patent application.
[2021/10]
Type: B1 Patent specification 
No.:EP3788035
Date:07.08.2024
Language:EN
[2024/32]
Search report(s)International search report - published on:EP05.12.2019
ClassificationIPC:C07D239/48, A61P35/00, A61K31/506
[2021/10]
CPC:
C07D239/48 (EP); C07D403/12 (US); A61P35/00 (EP);
C07B2200/13 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/10]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:FESTE FORMEN VON CERDULATINIB[2021/10]
English:SOLID FORMS OF CERDULATINIB[2021/10]
French:FORMES À L'ÉTAT SOLIDE DE CERDULATINIB[2021/10]
Entry into regional phase29.10.2020National basic fee paid 
29.10.2020Designation fee(s) paid 
29.10.2020Examination fee paid 
Examination procedure29.10.2020Examination requested  [2021/10]
29.10.2020Date on which the examining division has become responsible
16.06.2021Amendment by applicant (claims and/or description)
22.02.2023Despatch of a communication from the examining division (Time limit: M04)
16.06.2023Reply to a communication from the examining division
13.03.2024Communication of intention to grant the patent
13.06.2024Fee for grant paid
13.06.2024Fee for publishing/printing paid
13.06.2024Receipt of the translation of the claim(s)
Fees paidRenewal fee
27.05.2021Renewal fee patent year 03
27.05.2022Renewal fee patent year 04
30.05.2023Renewal fee patent year 05
27.06.2024Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.05.202406   M06   Fee paid on   27.06.2024
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2009145856  (PORTOLA PHARM INC [US], et al);
by applicantUS7514444
 US8138339
 US8501944
 US2013237493
 US8580794
 US8722657
 WO2016US34861
 WO2016US46862
 WO2016US64824
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.